SciBase Holding AB (OSTO:SCIB) Short Ratio


OSTO:SCIB SciBase Holding AB OSTO:SCIB
50 GF Score
Price kr33.25
GF Value kr21.73
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is SciBase Holding AB Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSTO:SCIB
50GF Score
SciBase Holding AB OSTO:SCIB
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?

Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued. The current stock price of kr33.25 is trading 53% above its estimated GF Value™ of kr21.73. GuruFocus considers SciBase Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:SCIB:

  • Short Ratio:
  • GF Value™: kr21.73 vs. price of kr33.25 (53% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SciBase Holding AB Business Description

Address Landsvagen 39, Sundbyberg, Stockholm, SWE, 172 63
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
50GF Score

Get the complete analysis for OSTO:SCIB

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr33.25
Price
kr21.73
GF Value